Hsin-Jung Wu

Hsin-Jung Wu has extensive experience in the field of pharmacology, with a focus on in vivo studies and anti-tumor immunity. Hsin-Jung has held roles as a Principal Scientist at Tango Therapeutics, a Sr. Scientist II at Blueprint Medicines, and a Sr. Scientist at Foghorn Therapeutics, Inc. In these positions, they have led in vivo studies, managed outsourced projects, and built internal capabilities. Hsin-Jung has also worked as a Scientist at Xilio Therapeutics, Inc., where they focused on in vivo pharmacology, and as a Scientist at Compass Therapeutics LLC, where they studied anti-tumor immunity using mouse tumor models. Hsin-Jung Wu's earlier experience includes working as a Postdoctoral Fellow at the University of Cincinnati College of Medicine, where they researched cell-cell communication within the tumor microenvironment, and as a Graduate Student Research Assistant at Indiana University Bloomington, where they conducted research on tissue regeneration using mesenchymal stem cells. Hsin-Jung also served as an Associate Instructor during their time at Indiana University Bloomington.

Hsin-Jung Wu received a Bachelor's degree in Public Health from National Taiwan University in 2007. From 2009 to 2015, they pursued a Doctor of Philosophy (Ph.D.) in Pharmacology at Indiana University Bloomington.